中商官网
研究报告
复星医药（HK2196）
| 科目\年度 | 2025-06-30 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
原始货币 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 审计意见 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 报表核心指标 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 现金及现金等价物净增加额 |
-- | -13892.80 | -174132.30 | 458200.80 | -73908.20 | -65932.60 | 111447.20 | 84272.50 | 198475.10 | 110897.30 | 30183.30 | 58494.70 | -172392.60 | 175534.40 |
| 经营活动现金流量净额 |
213400.00 | 447698.10 | 341421.70 | 421757.10 | 393781.50 | 257977.40 | 322241.30 | 295010.50 | 258022.60 | 211003.90 | 162102.80 | 120021.40 | 101163.30 | 66551.70 |
| 投资活动现金流量净额 |
-86000.00 | -361332.30 | -381929.00 | -406403.80 | -385748.90 | -470622.90 | -17196.20 | -524491.50 | -1050410.00 | -244709.50 | -186991.00 | -247833.70 | -180345.20 | -97508.00 |
| 融资活动现金流量净额 |
-146000.00 | -100258.60 | -133625.00 | 442847.50 | -81940.80 | 146712.90 | -193597.90 | 313753.50 | 990862.80 | 144602.90 | 55071.50 | 186307.00 | -93210.70 | 206490.70 |
| 现金及现金等价物期末余额 |
-- | 939145.00 | 950238.90 | 1117007.00 | 645971.70 | 732488.10 | 828437.10 | 717500.50 | 635031.90 | 453803.70 | 334859.40 | 301015.50 | 241626.10 | 417157.40 |
| 经营活动现金流量净额 |
213400.00 | 447698.10 | 341421.70 | 421757.10 | 393781.50 | 257977.40 | 322241.30 | 295010.50 | 258022.60 | 211003.90 | 162102.80 | 120021.40 | 101163.30 | 66551.70 |
| 折旧与摊销 |
-- | 317097.90 | 311867.80 | 244760.50 | 194844.80 | 172813.70 | 152047.90 | 134691.60 | 94591.00 | 73923.40 | 65731.09 | 56303.89 | 42049.80 | 29539.00 |
| 营运资金变动 |
-- | -101809.00 | -55076.50 | -131355.70 | 4382.10 | -116904.60 | -48786.50 | -35225.50 | -9914.50 | -15615.70 | -26743.90 | -51363.80 | -25290.20 | -8323.00 |
| 投资活动现金流量净额 |
-86000.00 | -361332.30 | -381929.00 | -406403.80 | -385748.90 | -470622.90 | -17196.20 | -524491.50 | -1050410.00 | -244709.50 | -186991.00 | -247833.70 | -180345.20 | -97508.00 |
| 资本性支出 |
-- | 441019.10 | 533670.50 | 588883.90 | 497279.90 | 443711.90 | 396205.90 | 317491.10 | 217061.70 | 192196.20 | 123553.60 | 111943.70 | 104005.50 | 116059.70 |
| 投资购买 |
-- | -21775.80 | -22764.00 | -101909.90 | -106678.40 | -64021.40 | -21236.50 | -11553.50 | -100970.80 | -36833.40 | -144948.80 | -33964.60 | -15375.60 | -17900.00 |
| 融资活动现金流量净额 |
-146000.00 | -100258.60 | -133625.00 | 442847.50 | -81940.80 | 146712.90 | -193597.90 | 313753.50 | 990862.80 | 144602.90 | 55071.50 | 186307.00 | -93210.70 | 206490.70 |
| 股份回购 |
-- | -23810.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 支付股息 |
-- | -112378.00 | -132835.50 | -157888.10 | -139509.10 | -136026.20 | -108522.50 | -117874.90 | -104669.40 | -84253.60 | -79146.59 | -78654.20 | -72405.30 | -39699.50 |
| 股票发行 |
-- | -- | 791.20 | 450945.30 | -- | -- | -- | 222457.40 | 203728.70 | 227585.00 | 2840.50 | 142333.60 | -- | 311834.80 |
| 现金及现金等价物净增加额 |
-- | -13892.80 | -174132.30 | 458200.80 | -73908.20 | -65932.60 | 111447.20 | 84272.50 | 198475.10 | 110897.30 | 30183.30 | 58494.70 | -172392.60 | 175534.40 |
| 加：现金及现金等价物期初余额 |
-- | 950238.90 | 1117007.00 | 645971.70 | 733351.10 | 828437.10 | 717500.50 | 635031.90 | 453803.70 | 334859.40 | 301015.50 | 241626.10 | 417157.40 | 242821.90 |
| 汇率变动对现金及现金等价物的影响 |
-- | 2798.90 | 7364.50 | 12834.20 | -13471.20 | -30016.40 | -510.60 | -1803.90 | -17246.90 | 8047.00 | 3660.60 | 894.70 | -3138.70 | -1198.90 |
| 现金及现金等价物期末余额 |
-- | 939145.00 | 950238.90 | 1117007.00 | 645971.70 | 732488.10 | 828437.10 | 717500.50 | 635031.90 | 453803.70 | 334859.40 | 301015.50 | 241626.10 | 417157.40 |